title: Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.
abstract: OBJECTIVE
  To verify the association between EGFR status and clinical response to microwave ablation (MWA) and survival.
  
  
  METHODS
  NSCLC patients with known EGFR status and treated with MWA in combination with chemotherapy were retrospectively enrolled in the study.
  
  
  RESULTS
  A total of 61 patients were recruited. EGFR mutations were found in 28 patients (39.4 %), and were more common in women (67.7 %) and nonsmokers (74.1 %). Complete ablation was achieved in 69.7 % of patients with EGFR mutant tumours and in 82.1 % of patients with EGFR wild-type tumours (p = 0.216). The median progression-free survival (PFS) and overall survival (OS) were 8.3 months and 27.2 months in patients with an EGFR mutant tumour. The corresponding values were 5.4 months (p = 0.162) and 17.8 months (p = 0.209) in patients with an EGFR wild-type tumour. Patients with complete ablation had longer PFS (7.8 months vs. 4.2 months, p = 0.024) and OS (28.1 months vs. 12.6 months, p = 0.001) than those with incomplete ablation. Multivariate analyses also showed that response to MWA was an independent prognostic factor for OS, but EGFR status was not, and that neither response to MWA nor EGFR status was a prognostic factor for PFS.
  
  
  CONCLUSIONS
  The EGFR status was not related to response to MWA, and response to MWA was a predictor of survival.
  
  
  CONCLUSIONS
  • EGFR mutations were commonly seen in women and in nonsmokers • EGFR status had no correlation with the response to MWA, PFS and OS. • The response to MWA could predict PFS and OS.
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Wei
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021. yexintaian2014@163.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Ye
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Xia
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Guanghui
authors.initials: G
authors.lastname: Huang
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Wenhong
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Jiao
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Han
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Min
authors.initials: M
authors.lastname: Meng
authors.affiliation: Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwuweiqi Road, Jinan, Shandong Province, China, 250021.
authors.forename: Yang
authors.initials: Y
authors.lastname: Ni
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003972:Diathermy / Q000379:methods*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008872:Microwaves / Q000627:therapeutic use*; D008875:Middle Aged; D009154:Mutation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D066246:ErbB Receptors
keywords: EGFR mutation; Microwave ablation; Non-small-cell lung cancer; Overall survival; Progression-free survival